This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Seattle-based Adaptive Biotechnologies and Microsoft have launched an open-access database called ImmuneCODE to catalog the many ways in which our immune systems fight off a coronavirus infection. Check out this GeekWire Health Tech Podcast for more about Adaptive Biotechnologies’ collaboration with Microsoft on COVID-19 studies.
Nautilus Biotechnology co-founder Sujal Patel. Shares of Nautilus Biotechnology rose by as much as 50% on Thursday morning after a report revealed that Amazon has taken an equity stake in the newly public Seattle-based company. Nautilus Photo).
As one of the first partners of ATI, the biotechnology company hired interns to form a team of data stewards to work on a significant data segmentation project. The interns were specifically responsible to verify the accuracy and reliability of data, working alongside the team to ensure they adhere to compliance and regulatory policies.
Less than three years after it was founded and with no revenue on the books, Sana Biotechnology has f iled to go public. And like many biotechnology companies it is losing money. Sana would become the latest in a string of Seattle area biotechnology companies to join the public ranks in recent months. stake in Sana.
Sana Biotechnology CEO Steve Harr cuts the ribbon at the company’s new manufacturing facility in Bothell, Wash., Sana Biotechnology CEO Steve Harr outside the company’s new manufacturing facility in Bothell, Wash., Washington state Rep. on Friday at a ribbon-cutting ceremony.
Oisín Biotechnologies , a Seattle-based startup focused on treating aging-related diseases, raised $15 million in a Series A round led by AbbVie Ventures. The company is developing preclinical therapies to eliminate unwanted fat cells and build muscle mass to address frailty.
Adaptive Photo) — Mark Adams is stepping down as chief operating officer of Adaptive Biotechnologies , the company said today in a regulatory filing. Sana Biotechnology named two new research leaders. Mark Adams. Adams joined the Seattle-based biotech giant more than three years ago.
Sana Biotechnology — the Seattle upstart that’s looking to treat a variety of diseases through gene therapy and cell engineering — is generating buzz on Wall Street. That would net the biotechnology company $517 million if it sold at the midpoint of that range. Sana’s technology (screen grab via IPO filing).
Sana Biotechnology will reduce its workforce by 29%, the Seattle-based cell and gene therapy company revealed in a SEC filing Tuesday. The company said it is increasing focus on its ex vivo cell therapy product candidates, resulting in a “strategic re-positioning” and delaying other projects.
Sana Biotechnology , a young and fast-growing Seattle-based biotech, has chosen the San Francisco Bay Area as the site for its new biomanufacturing facility. Competition for researchers skilled in biomanufacturing and other areas can be stiff, and the Bay Area is a much larger, more established biotechnology hub than Seattle.
Adaptive Biotechnologies). Adaptive Biotechnologies has promoted one exec, while another is departing next month. Adaptive Biotechnologies’ EVP of Operations and Management Nancy Hill will depart the company in March. Bevier joined the F5 board in 2006. Mark Adams. Mark Adams is now COO.
Chad Robins, left, is co-founder and CEO of Adaptive Biotechnologies, which he co-founded with his brother, Harlan Robins, right, the company’s chief scientific officer. Adaptive Biotechnologies Photo). Adaptive Biotechnologies is laying off 12% of its workforce, or about 100 employees, GeekWire has learned. “We
Sana Biotechnology has a new $50 million tool in its toolbox. Sana CEO and president Steve Harr. Sana Photo). Sana signed an agreement with Beam Therapeutics for non-exclusive commercial rights to the Cambridge, Mass.-based based biotech’s gene editing system, called CRISPR-Cas12b.
Other spinouts associated with the institute include Cyrus Biotechnology , Sana Biotechnology , A-Alpha Bio and Xaira Therapeutics. AstraZeneca paid $1.1 billion to acquire a different spinout, Icosavax , which develops synthetic vaccines that target naturally occurring viruses.
Biotechnology and synthetic biology: The swift development of mRNA vaccines in 2020 illustrated biotechs unprecedented speed in delivering transformative products. Quantum services are already available via cloud platforms, addressing complex issues in chemistry and logistics. CRISPR) for personalized medicine and drought-resistant crops.
Seattle-based cell and gene therapy company Sana Biotechnology will reduce its workforce by 15%, according to a statement issued Tuesday. Adaptive Biotechnologies , Absci , and Zymeworks also announced layoffs this year. Sana CEO Steve Harr. Sana Photo). Seattle startup TwinStrand Biosciences also reportedly laid off staff.
Adaptive Biotechnologies , which develops technology to assess the immune response, posted $154.3 Adaptive moved into its new headquarters in September. Co-founders Harlan (left) and Chad Robins on the new plaza. GeekWire Photo / Charlotte Schubert). million in revenue last year, a 57% year-over-year increase.
Adaptive Biotechnologies has a new CFO. Tycho Peterson, Adaptive’s new CFO. Morgan Chase Photo). Tycho Peterson comes from J.P. Morgan Chase, where he most recently served in its healthcare group as managing director, life science tools and diagnostics.
A biotech prize for turning chemicals into food On the biotechnology front, the Mars Society plans to offer an incentive prize for methods that use microbes to convert simple chemicals, such as methane or methanol, into food. “Ask it anything you want, and you get the answer in multiple personalities,” he said.
Adaptive co-founders Harlan (left) and Chad Robins on the plaza at the new Adaptive Biotechnology headquarters. After doubling its workforce during the pandemic, Adaptive Biotechnologies finally has room to grow. GeekWire Photos / Charlotte Schubert).
Chad Robins, CEO of Adaptive Biotechnologies, speaks at the site of the company’s future corporate headquarters in Seattle, standing in front of the final piece of structural steel before it’s put into place. Stephen Brashear/AP Images for Adaptive Biotechnologies). Stephen Brashear/AP Images for Adaptive Biotechnologies).
Chad Robins, left, is co-founder and CEO of Adaptive Biotechnologies, which he co-founded with his brother, Harlan Robins, right, a theoretical physicist turned computational biologist who is the company’s chief scientific officer. Adaptive Biotechnologies Photo).
In the previous four years, Adaptive Biotechnologies was the only Washington state biotech company to go public. Sana Biotechnology, for instance, is led by Steve Harr , former CFO and corporate development head at Juno Therapeutics, a Seattle company that went public in 2014 and was later acquired by Celgene for $9 billion.
OncoSenX is the spinoff of a third company, Seattle-based Oisin Biotechnologies. The researchers said they have selected the two most promising DNA sequences for further testing. Researchers at OncoSenX are using Fusogenix for cancer research on the treatment of solid tumors.
Absci is the latest in a string of Washington state biotech startups to test the public markets — others including Impel Neuropharma, Sana Biotechnology, Athira Pharma, and Silverback Therapeutics have had IPOs in the past year. The amount of investment that is pouring into biotechnology and the life sciences is incredible,” said Alexandre.
The UK Space Agency and BiologIC Technologies are partnering to develop advanced biotechnologies, including vaccines and gene therapies, for space manufacturing.
That’s the case for Yi Zhou, CTO and CIO with Adaptive Biotechnologies. In today’s dynamic business environment, IT must transcend traditional roles,” Adaptive Biotechnologies’ Zhou says. He plans to scale his company’s experimental generative AI initiatives “and evolve into an AI-native enterprise” in 2024.
OncoSenX is a spinout out of Oisin Biotechnologies, a 5-year-old Seattle company also led by Scholz, a veteran biotech entrepreneur. The Seattle-based company just extended its oversubscribed SAFE (Simple Agreement for Future Equity) to allow for more capital, confirmed CEO Matthew Scholz. million to date.
The amount of investment that is pouring into biotechnology and the life sciences is incredible,” said Leslie Alexandre, CEO of Life Sciences Washington. Biotech IPOs reached an all-time high last year, according to Biopharma Dive , and the pace is continuing into 2021.
Others include Sana Biotechnology, Chinook Therapeutics, Kineta, Alpine Immune Sciences, Adaptive Biotechnologies, and more, in addition to work being done at Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Benaroya Research Institute, and others.
Adaptive Biotechnologies says it’s proceeding with plans to launch a new type of test to determine if someone was previously infected with SARS-CoV-2, the virus that causes COVID-19, after a study added to the evidence that its approach is more accurate than currently available antibody tests. Adaptive Biotechnologies Photo).
Nautilus Biotechnology Photo) — After more than two decades at scientific instruments company Agilent Technologies, Ken Suzuki is now chief marketing officer for Nautilus Biotechnology. ” Ken Suzuki. Seattle-based Nautilus has designed a platform for analyzing proteomes, a term for the proteins produced by an organism.
In June, Seattle biotechnology upstart Sana Biotechnology revealed that it had raised more than $700 million in venture funding. Which of these Washington state companies did NOT go public in 2020: Accolade, Adaptive Biotechnologies, Athira Pharma, Silverback Therapeutics? Adaptive Biotechnologies (It went public in 2019).
The company, founded in 2011, began commercial operations in 2018 and now has partnerships with Merck, Xyphos Biotechnology, Alpha Cancer Technologies and several other drug companies. Three Washington state companies — Sana Biotechnology , Impel Neuropharma and Paymentus — have gone public with a traditional IPO this year.
Chad Robins, left, is co-founder and CEO of Adaptive Biotechnologies, which he co-founded with his brother, Harlan Robins, right, a theoretical physicist turned computational biologist who is the company’s chief scientific officer. Adaptive Biotechnologies Photo).
The work, led by Professor Ross King from the University of Cambridge Department of Chemical Engineering and Biotechnology, teaches computers to learn more like how humans do—by building on what’s been learned in the past. .
This is the first such incubator, funded by the government’s Department of Biotechnology, to be set up in a medical college,” claims Rath. “Till now, such incubators were set up by the government in IITs and other engineering colleges.
This was a first-of-its kind diagnostic tool from Seattle-based Adaptive Biotechnologies , a company that develops technology to sequence the human immune system for the diagnosis and treatment of disease. Adaptive Biotechnologies’ new test, called T-Detect COVID , was developed in partnership with Microsoft.
Spinout success: Other Fred Hutch spinouts include Juno Therapeutics and Adaptive Biotechnologies, while University of Washington research led to the launch of Icosavax, Neoleukin Therapeutics, Universal Cells, Cyrus Biotechnology and others.
The Bill & Melinda Gates Foundation has committed $40 million in equity investment and $10 million in grant funding to Vir Biotechnology for the development of therapies against HIV and Malaria, Vir announced Friday. government has been buying to fight Omicron.
Adaptive Biotechnologies CEO Chad Robins. Adaptive Biotechnologies, which is working with Microsoft and Amgen to fight COVID-19 using its technology for sequencing the human immune system, reported a 65% increase in first quarter revenue , to nearly $21 million. GeekWire File Photo). The Seattle-based company posted a net loss of $31.4
This week Seattle-based Nautilus Biotechnology, led by Isilon Systems co-founder Sujal Patel, went public via a SPAC merger. Remitly, ranked No. 3 on the GeekWire 200 list of top Pacific Northwest tech startups, has around 1,000 employees across its Seattle HQ and six other offices in Spokane, Wash.,
Pacific Northwest biotechs that have gone public this year include Sana Biotechnology, which raised $587 million in its February IPO and Impel NeuroPharma, which raised $80 million through its IPO in April.
Formerly known as M3 Biotechnology, the company is led by Dr. Leen Kawas , a 35-year-old CEO who will be the first woman to guide a company to an initial public offering in Washington state in more than two decades. It is the first Seattle biotech to go public since Adaptive Biotechnologies IPO’d last year.
We organize all of the trending information in your field so you don't have to. Join 83,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content